drugset / Trial / NCT00388440
Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
Non-randomizedSingle-groupOpen-labelPrevention
Summary
To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy children (12-18 months of age) and blood samples were collected at two time points (before vaccination and after vaccination).
Timeline
- Start
- 2000-11
- Primary completion
- 2001-04
- Completion
- 2001-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Priorix | Vaccine | — | — |